文献速递心境障碍儿童青少年精神

围产期重度抑郁障碍的全球患病率:系统综述与元回归

The global prevalence of major depressive disorder during the peripartum period: a systematic review and meta-regression.
PubMed 文献 · Lancet Psychiatry · 2026-04-30

该系统综述与元回归纳入780项研究、1505个患病率数据点,覆盖90个国家2 018 198名10-59岁女性,评估围产期重度抑郁障碍(MDD)的全球患病率及数据异质性来源。

要点

  • 症状量表相较诊断性访谈会明显高估MDD患病率,临床解读筛查阳性需谨慎。
  • 产后一年内MDD患病率持续高于孕期,产后前2周达峰值。
  • 南撒哈拉以南非洲与南亚患病率最高,高收入亚太地区最低。

核心结论

  • 围产期MDD患病率在整个围产期均升高,产后2周最高,应加强筛查、预防与治疗整合到现有照护模式中。

研究设计与样本

  • 系统综述与元回归,检索PubMed、Embase、PsycINFO及灰色文献,纳入1980年1月1日至2025年10月23日发表的横断面或纵向调查。
  • MDD采用DSM或ICD标准定义,对象为10-59岁女性,覆盖孕期至产后12个月,遵循PRISMA指南(PROSPERO ID CRD42022358108)。

主要发现

  • 从31 812项潜在 eligible 研究中筛选25 616项题录摘要,1025项进入定性合成,780项研究的1505个患病率数据点进入第二阶段分析。
  • 产后前2周MDD患病率最高(p<0·0001),整个产后一年均显著高于孕期(p<0·0001)。

关键数值与推荐

  • MDD定义采用DSM或ICD标准,患病率数据为非可识别且预先汇总的既有来源数据。
  • 多数研究纳入医院围产保健人群,其服务区域具有人群代表性;优先纳入覆盖全孕周的研究,亦纳入仅限单胎或足月产的研究。
  • 产后前2周患病率最高(p<0·0001),产后一年内持续显著高于孕期(p<0·0001)。

临床怎么用

  • 围产期应全程关注MDD风险,尤其产后前2周及产后一年内,不宜仅限孕期筛查。
  • 症状量表筛查阳性不能等同于MDD诊断,需结合诊断性访谈确认。
  • 南撒哈拉以南非洲与南亚等高患病率地区应优先加强筛查、预防与治疗服务整合。

局限性

  • 作者团队虽具精神障碍亲历经验,但未咨询围产期MDD确诊个体。
  • 患病率数据为预先汇总的非可识别数据,元回归用于量化现有数据中的测量误差来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For a meaningful global health response to major depressive disorder (MDD) during the peripartum period, its global distribution needs to be understood. The aim of this study was to conduct a systematic review of the prevalence of MDD during the peripartum period to assess sources of data heterogeneity and trends in prevalence during pregnancy and the postpartum period. METHODS: This systematic review and meta-regression quantified MDD during pregnancy and up to 12 months postpartum among women and girls aged 10-59 years, across world regions. We searched PubMed, Embase, PsycINFO, and grey literature sources for studies published between Jan 1, 1980, and Oct 23, 2025. We included data from cross-sectional or longitudinal surveys of women and girls assessing the prevalence of MDD during the peripartum period. MDD was defined with criteria from the DSM or ICD. Most studies included patients receiving perinatal care from hospitals with population-representative catchments. Preference was given to studies encompassing pregnancies of all gestational lengths; however, studies restricted to singleton or full-term births were included. Extracted prevalence data were non-identifiable and pre-aggregated from existing sources. Records generated in the electronic and grey literature searches were combined and titles, abstracts, and full texts were reviewed by AJF, PAM, JS, AMH, SMA, and PM. Their decisions and related disagreements were reviewed by senior authors (AJF and DFS). The meta-regression analysis quantified sources of measurement error within the available data and assessed the prevalence of MDD during the peripartum period and by location. We followed the PRISMA guidelines (PROSPERO ID CRD42022358108). Members of our authorship team have lived experience perspectives in mental disorders, but we did not consult individuals diagnosed with MDD during the peripartum period. FINDINGS: Of 31 812 potentially eligible studies, we screened the titles and abstracts of 25 616 studies, and included 1025 studies in the qualitative synthesis. We included 1505 prevalence datapoints from 780 studies eligible for stage two analysis, representing 2 018 198 women and girls from 90 countries and 19 world regions. Symptom scales identifying MDD symptoms overestimated its prevalence by between 71·3% (95% uncertainty interval [UI] 54·3-89·8) for the Edinburgh Postnatal Depression Scale in the postpartum period and 121·9% (91·7-156·8) for Patient Health Questionnaire during pregnancy, compared with diagnostic interview. MDD prevalence during the peripartum period was highest during the first 2 weeks postpartum (p<0·0001) and remained significantly elevated throughout the postpartum year (p<0·0001) compared with pregnancy. After adjusting for changes over the peripartum period and biases due to measurement error, the overall prevalence of MDD was 6·2% (95% UI 5·9-6·6) at any point in time during pregnancy and 6·8% (6·4-7·1) at any point in time during the postpartum year. Prevalence was highest in southern sub-Saharan Africa, ranging from 15·6% (12·7-19·1) during pregnancy to 16·6% (13·5-20·3) during the postpartum year; and south Asia, ranging from 13·7% (12·4-15·2) during pregnancy to 14·6% (13·1-16·1) during the postpartum year. The prevalence was lowest in high-income Asia Pacific, ranging from 3·1% (2·5-3·7) during pregnancy to 3·3% (2·8-3·9) during the postpartum year. INTERPRETATION: The prevalence of MDD was elevated during the entire peripartum period, and highest 2 weeks after giving birth. Our findings emphasise the need for increased integration of screening, prevention, and treatment of MDD during the peripartum period into existing models of care. FUNDING: Queensland Health, The University of Queensland, and Gates Foundation.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ferrari AJ, Miller PA, Shadid J, et al. The global prevalence of major depressive disorder during the peripartum period: a systematic review and meta-regression. Lancet Psychiatry. 2026. PMID: 42070579. doi:10.1016/S2215-0366(26)00085-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。